Literature DB >> 30802185

Effects of a Disease Management Program for Preventing Recurrent Ischemic Stroke.

Yasuko Fukuoka1, Naohisa Hosomi2, Takeshi Hyakuta3, Toyonori Omori4, Yasuhiro Ito5, Jyunichi Uemura6, Yoshiki Yagita6, Kazumi Kimura7, Masayasu Matsumoto2, Michiko Moriyama1.   

Abstract

Background and Purpose- Disease management is a healthcare strategy that includes self-management education and treatment coordination. We conducted a randomized controlled trial to determine whether a disease management program intervention could improve risk factor profiles and, thus, reduce the recurrence of stroke and other cardiovascular diseases. Methods- This study is a prospective randomized, open-label, parallel group study involving outpatients with a history of stroke. Between September 2010 and November 2012, we enrolled patients aged between 40 and 80 years who experienced their last ischemic stroke event or transient ischemic attack within 1 year. After stratifying by the ischemic stroke subtype, 321 subjects (67.5±8.5 years, 95 female) were randomly assigned to either the disease management program intervention group (n=156) or the usual care group (n=165). The primary end point of this study was the difference in the Framingham risk score (general cardiovascular disease 10-year risk) from baseline. The secondary end points of this study included stroke recurrence, onset of cardiovascular disease, all-cause mortality, and all vascular events. Results- Regarding the primary end point, there was no significant difference in the changes in the Framingham risk score at any follow-up time between the groups. The incidence of stroke recurrence tended to be lower in the disease management program intervention group, although no significant difference was found (hazard ratio, 0.49; 95% CI, 0.19-1.29). Conclusions- We were unable to demonstrate a clear benefit of disease management program intervention. Clinical Trial Registration- URL: https://www.clinicaltrials.gov . Unique identifier: NCT02121327.

Entities:  

Keywords:  disease management; recurrence; risk factors; stroke

Mesh:

Year:  2019        PMID: 30802185     DOI: 10.1161/STROKEAHA.118.020888

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  4 in total

1.  STROKE-CARD care to prevent cardiovascular events and improve quality of life after acute ischaemic stroke or TIA: A randomised clinical trial.

Authors:  Peter Willeit; Thomas Toell; Christian Boehme; Stefan Krebs; Lukas Mayer; Clemens Lang; Lisa Seekircher; Lena Tschiderer; Karin Willeit; Gerhard Rumpold; Gudrun Schoenherr; Andrea Griesmacher; Julia Ferrari; Michael Knoflach; Wilfried Lang; Stefan Kiechl; Johann Willeit
Journal:  EClinicalMedicine       Date:  2020-07-28

2.  Study on the Mechanism of Üstikuddus Sherbiti in Ischemic Cerebrovascular Diseases: Based on Network Pharmacology.

Authors:  Aman Gul; Mutalifu Aimaiti; Tuerhong Tuerxun; Raziye Amat; Ayinuer Reheman; Min Fang Zhang; Nassirhadjy Memtily
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-08       Impact factor: 2.650

3.  Long-term outcome of a pragmatic trial of multifaceted intervention (STROKE-CARD care) to reduce cardiovascular risk and improve quality-of-life after ischaemic stroke and transient ischaemic attack: study protocol.

Authors:  Christian Boehme; Lena Domig; Silvia Komarek; Thomas Toell; Lukas Mayer; Benjamin Dejakum; Stefan Krebs; Raimund Pechlaner; Alexandra Bernegger; Christoph Mueller; Gerhard Rumpold; Andrea Griesmacher; Marion Vigl; Gudrun Schoenherr; Christoph Schmidauer; Julia Ferrari; Wilfried Lang; Michael Knoflach; Stefan Kiechl
Journal:  BMC Cardiovasc Disord       Date:  2022-08-01       Impact factor: 2.174

4.  The Effectiveness of Telenursing for Self-Management Education on Cardiometabolic Conditions: A Pilot Project on a Remote Island of Ōsakikamijima, Japan.

Authors:  Michiko Moriyama; Kana Kazawa; Yasmin Jahan; Mika Ikeda; Mariko Mizukawa; Yasuko Fukuoka; Koji Harada; Md Moshiur Rahman
Journal:  J Prim Care Community Health       Date:  2021 Jan-Dec
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.